Contract Notice Detail
Summary Information
Summary Information
Base Total Price:
225,750.000000 Euro
Request Reference:
Q1/2119/2024 - AGREGAÇÃO URGENTE - INFLIXIMAB 100M
Request Name:
Q1/2119/2024 - AGREGAÇÃO URGENTE - INFLIXIMAB 100MG PO CONC SOL INJ IV
Phase:
Tendering Phase
State:
Awarded
Description:
Q1/2119/2024 - AGREGAÇÃO URGENTE - INFLIXIMAB 100MG PO CONC SOL INJ IV
Procedure Type:
VortalGOV - Acquisition under a Framework Agreement (via Direct Award)
Lot Name
Lot Base Price
Expected Duration
I251 - INFLIXIMAB [100 MG; PÓ P/A CONC P/A SOL P/A PERF; FRS]
-
6
(
Months
)
Object of the Contract
Object of the Contract
Type of Contract:
Supplies Acquisition
Main Object CPV Main Category:
Rua das Olhalvas 2410-197 União das freguesias de Leiria, Pousos, Barreira e Cortes Leiria PORTUGAL
CPV Main Vocabulary
33600000-6 - Pharmaceutical products
CPV Supplementary Vocabulary
Additional Classifications List
Scheduling
Scheduling
Request online publishing date:
6/21/2024 2:08 PM
(UTC +1 hour)
National official publishing date and time (DR):
9/4/2023 2:03 PM
(UTC +1 hour)
Due datetime for receiving replies:
6/26/2024 6:00 PM
(UTC +1 hour)
Financial Settings
Financial Settings
Define Warranties?
No
Contract Documents
Contract Documents
Document Name
Description
Doc Classification
Q1000021192024.xlsx
Q1000021192024.xlsx
Download
Q1 2119 CONVITE.pdf
Q1 2119 CONVITE.pdf
Download
Object of contract
This contract is subject to renewal?
No
The procurement is related to a project and/or programme financed by European Union funds?
No
Legal, economic, financial and technical information
The contract is reserved to sheltered workshops and economic operators aiming at the social and professional integration of disabled or disadvantaged persons?
No
Questionnaire
Questionnaire
1
Lot Title
I251 - INFLIXIMAB [100 MG; PÓ P/A CONC P/A SOL P/A PERF; FRS]
Base Price
225 750,000000
1.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
I251
INFLIXIMAB [100 MG; PÓ P/A CONC P/A SOL P/A PERF; FRS]
3 500,000000
NXTWY.UMT.14950
Buyer Comment:
500191360 | Merck Sharp & Dohme, Lda. | CPA:2023491/193/0436 | NºAIM:2972289; 506415740 | Biogen Portugal - Sociedade Farmacêutica, Unipessoal, Lda. | CPA:2023491/320/0131 | NºAIM:5684923; 506985261 | Sandoz Farmacêutica, Lda. | CPA:2023491/326/0644 | NºAIM:5754759; 507002571 | Pharmakern Portugal, Produtos Farmacêuticos Soc. Unipessoal, Lda. | CPA:2023491/379/0406 | NºAIM:5579115;
TOTAL
(The amounts shown do not include VAT)
Evaluation
Evaluation
Vision
Avaliação
Definir modelo de avaliação
Sim
Não
Modalidade de avaliação
Selecione…
Monofator
Método de Avaliação
Selecione…
Manual
Divulgar critérios de avaliação
Sim
Não
Critérios da Avaliação
1 - I251 - INFLIXIMAB [100 MG; PÓ P/A CONC P/A SOL P/A PERF; FRS]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
-
100%
Normas de desempate
Public Messages
Public Messages
Type
Reference
Subject
Date
No items found...